An experimental vaccine against American dermal leishmaniasis: experience in the State of Espírito Santo, Brazil.
A vaccine prepared from killed and sonicated promastigotes of five Brazilian strains of Leishmania was used during an epidemic of American dermal leishmaniasis that occurred in Viana county, State of Espírito Santo, Brazil. Initially, all of the participants in the vaccination programme had negative reactions to Montenegro antigen. Forty days after the last dose of vaccine had been given, 87.6% of the 216 vaccinated individuals had become Montenegro-positive whereas the 266 unvaccinated persons remained Montenegro-negative. The study area had an unstable population and details are given about the human population changes that occurred during the two-year study period. Taking into account population movements, 1.5% of those vaccinated and 6.4% of the unvaccinated group developed dermal leishmanial lesions by the end of the first year. At the end of the second year, 1.7% of those vaccinated and 8.9% of the unvaccinated group had become infected. The difference in infection rates of the two groups is statistically significant at both the end of the first and second years of observation. Diagnosis of the disease(s) was based on the clinical appearance of lesions combined with parasitological and/or immunological evidence and subsequent responses to treatment. The experience gained in Viana also provided information about the storage and administration of the experimental vaccine which have been used in mounting a randomized clinical trial.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000953:Antigens, Protozoan / Q000276:immunology; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D003710:Demography; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007891:Leishmania / Q000276:immunology; D007896:Leishmaniasis / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D014611:Vaccination; D014612:Vaccines
D000953:Antigens, Protozoan; D014612:Vaccines